Rising

GLP-1 Oral Market Competition: Lilly Foundayo vs. Novo Wegovy

Goldman Sachs projects Eli Lilly to capture 60% of the daily oral market by 2030 (approximately $13.6 billion) versus Novo Nordisk's 21% (approximately $4 billion).

Primary sources · 1

Pharma Tech

← View the full 2026-04-23 (Wed) issue

What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →